ADAPTIVE AND INNATE IMMUNE RESPONSES
TRIGGERED TO NEUTRALIZE GASTRIN HORMONES
AS A THERAPY FOR GI CANCERS

NEWS FLASH

March 2016: OncoQR and TYG oncology Ltd announce the expansion of their collaboration agreement to tackle additional cancers. http://tinyurl.com/zcyzelp

March 2016: OncoQR announces the preclinical dose-ranging findings for TYG100. A single dose achieved clinical levels of antibodies in NHP including patients treated concurrently with gemcitabine. 
http://tinyurl.com/jptsq4z

February 2016:  Experimental Cancer Medicines Centres in Leeds, Glasgow and Belfast design parallel first-in-human trials in pancreatic and gastroesophageal cancers for TYG100.

November 2014: TYG oncology files for patent protection of TYG100.

April 2014: on behalf of TYG, Dr. Paul Broome presented the TYG100 technology at the annual AACR meeting. Historically clinically relevant titres of gastrin neutralising antibodies obtained in earlier Phase 3 trials were exceeded >100 fold with TYG100 with no serious adverse events.

March 2014:  DANIEL D. VON HOFF, M.D., F.A.C.P., a world renowned expert in the field of pancreatic advises the company on critical Phase 2 trial design.

March 2014:  GRAHAM DOCKRAY, Emeritus Professor of Physiology at the University of Liverpool, is welcomed as a new member of it's scientific advisory board January 2013: TYG oncology Ltd registered - Companies House, UK. 

[Sleeker_special_clear]